Latest news with #ViatrisInc
Yahoo
3 days ago
- Business
- Yahoo
Viatris Provides Update on Phase 3 Study of MR-139 for Blepharitis
PITTSBURGH, July 18, 2025 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that a randomized, double-masked, vehicle-controlled, Phase 3 study to evaluate the efficacy and safety of pimecrolimus 0.3% (MR-139) ophthalmic ointment in subjects with blepharitis, did not meet its primary endpoint of complete resolution of debris after six weeks of twice daily dosing. Viatris Chief R&D Officer Philippe Martin said, "Given that the study did not meet its objective for patients suffering from blepharitis, we are evaluating the appropriate next steps for the Phase 3 program, which may include revising the planned additional Phase 3 study. Thank you to the patients and investigators who contributed to the trial." The Company is focused on delivering novel therapies like Tyrvaya® and RYZUMVI®, while progressing a differentiated pipeline that addresses unmet needs in anterior segment conditions. In June 2025, Viatris announced positive top-line results from its Phase 3 LYNX-2 trial of MR-142 in keratorefractive patients experiencing visual disturbances under mesopic, low-contrast conditions. The Company also announced positive top-line results from its second pivotal Phase 3 VEGA-3 Trial of MR-141 in treating presbyopia. About the MR-139 3001 Phase 3 StudyThe MR-139 3001 Phase 3 trial consisted of a randomized, placebo-controlled, double-masked prospective study, with a total of 477 patients who were randomized to receive either MR-139 or placebo, self-administered to the eyelids twice daily, treated and observed over 12 weeks. For more information on the MR-139 study design, refer to (NCT06400511). About ViatrisViatris Inc. (Nasdaq: VTRS) is a global healthcare company uniquely positioned to bridge the traditional divide between generics and brands, combining the best of both to more holistically address healthcare needs globally. With a mission to empower people worldwide to live healthier at every stage of life, we provide access at scale, currently supplying high-quality medicines to approximately 1 billion patients around the world annually and touching all of life's moments, from birth to the end of life, acute conditions to chronic diseases. With our exceptionally extensive and diverse portfolio of medicines, a one-of-a-kind global supply chain designed to reach more people when and where they need them, and the scientific expertise to address some of the world's most enduring health challenges, access takes on deep meaning at Viatris. We are headquartered in the U.S., with global centers in Pittsburgh, Shanghai and Hyderabad, India. Learn more at and and connect with us on LinkedIn, Instagram, YouTube and X (formerly Twitter). Forward-Looking StatementsThis press release includes statements that constitute "forward-looking statements." These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements may include statements that a randomized, double-masked, vehicle-controlled, Phase 3 study to evaluate the efficacy and safety of pimecrolimus 0.3% (MR-139) ophthalmic ointment in subjects with blepharitis, did not meet its primary endpoint of complete resolution of debris after six weeks of twice daily dosing; given that the study did not meet its objective for patients suffering from blepharitis, we are evaluating the appropriate next steps for the Phase 3 program, which may include revising the planned additional Phase 3 study; the Company is focused on delivering novel therapies like Tyrvaya® and RYZUMVI®, while progressing a differentiated pipeline that addresses unmet needs in anterior segment conditions; in June 2025, Viatris announced positive top-line results from its Phase 3 LYNX-2 trial of MR-142 in keratorefractive patients experiencing visual disturbances under mesopic, low-contrast conditions; and the Company also announced positive top-line results from its second pivotal Phase 3 VEGA-3 Trial of MR-141 in treating presbyopia. Because forward-looking statements inherently involve risks and uncertainties, actual future results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to: the uncertainties inherent in research and development, including the outcomes of clinical trials; the ability to meet anticipated clinical endpoints; the possibility of unfavorable new clinical data and further analyses of existing clinical data; the risk that clinical trial data are subject to differing interpretations and assessments by regulatory authorities; whether regulatory authorities will be satisfied with the design of and results from clinical studies; actions and decisions of healthcare and pharmaceutical regulators; our ability to comply with applicable laws and regulations; changes in healthcare and pharmaceutical laws and regulations in the U.S. and abroad; any regulatory, legal or other impediments to Viatris' ability to bring new products to market; products in development and/or that receive regulatory approval may not achieve expected levels of market acceptance, efficacy or safety; longer review, response and approval times as a result of evolving regulatory priorities and reductions in personnel at health agencies; Viatris' or its partners' ability to develop, manufacture, and commercialize products; the scope, timing and outcome of any ongoing legal proceedings, and the impact of any such proceedings on Viatris; Viatris' failure to achieve expected or targeted future financial and operating performance and results; goodwill or impairment charges or other losses; any changes in or difficulties with the Company's manufacturing facilities; risks associated with international operations; changes in third-party relationships; the effect of any changes in Viatris' or its partners' customer and supplier relationships and customer purchasing patterns; the impacts of competition; changes in the economic and financial conditions of Viatris or its partners; uncertainties regarding future demand, pricing and reimbursement for the Company's products; uncertainties and matters beyond the control of management, including but not limited to general political and economic conditions, potential adverse impacts from future tariffs and trade restrictions, inflation rates and global exchange rates; and the other risks described in Viatris' filings with the Securities and Exchange Commission ("SEC"). Viatris routinely uses its website as a means of disclosing material information to the public in a broad, non-exclusionary manner for purposes of the SEC's Regulation Fair Disclosure (Reg FD). Viatris undertakes no obligation to update these statements for revisions or changes after the date of this press release other than as required by law. View original content to download multimedia: SOURCE Viatris Inc. Sign in to access your portfolio
Yahoo
3 days ago
- Business
- Yahoo
Viatris (VTRS) Announces Positive Top-line Results from VEGA-3
Viatris Inc. (NASDAQ:VTRS) is one of the The company announced positive top-line results from VEGA-3, which is the second pivotal Phase 3 trial evaluating MR-141 (phentolamine ophthalmic solution 0.75%) in treating presbyopia. To give a brief overview, presbyopia happens to be a progressive loss of the ability to focus on close objects, which leads to blurred near vision and eye strain, mainly in dim lighting conditions. A healthcare worker in a lab coat, holding a microscope and reflecting on the diagnosis of a patient. As per Viatris Inc. (NASDAQ:VTRS)'s Chief R&D Officer, presbyopia is a very common condition that affects ~90% of adults in the US over the age of 45. Viatris Inc. (NASDAQ:VTRS) expressed optimism with the positive results from the second pivotal Phase 3 trial, which reinforce the company's confidence in MR-141 and its benefit-risk profile as a potential, non-invasive option to help millions of patients. Furthermore, Viatris Inc. (NASDAQ:VTRS)'s growing pipeline, capital discipline, operational execution, and strong global scope provide confidence to navigate the periods of volatility and uncertainty. Viatris Inc. (NASDAQ:VTRS) continues to generate strong cash flow. Its net cash provided by operating activities (US GAAP) came in at $535 million, and FCF was $493 million, which includes $43 million in transaction-related costs. While we acknowledge the potential of VTRS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 13 Cheap AI Stocks to Buy According to Analysts and 11 Unstoppable Growth Stocks to Invest in Now Disclosure: None. This article is originally published at Insider Monkey.
Yahoo
6 days ago
- Business
- Yahoo
Viatris Gains China Approval for COPD Drug Yupelri, Triggers $7.5M Payment to Theravance BioPharma
Viatris Inc. (NASDAQ:VTRS) is one of the best low priced pharma stocks to buy now. On June 27, Viatris received approval from China's National Medical Products Administration/NMPA for Yupelri (revefenacin) inhalation solution for the maintenance treatment of chronic obstructive pulmonary disease/COPD. Yupelri is the first ever once-daily nebulized long-acting muscarinic antagonist/LAMA approved in China for COPD. Yupelri's mechanism of action involves inhibiting M3 receptors in the smooth muscle, leading to bronchodilation. A healthcare worker in a lab coat, holding a microscope and reflecting on the diagnosis of a patient. This milestone triggers a one-time payment of $7.5 million from Viatris to Theravance Biopharma Inc. (NASDAQ:TBPH), which is expected in Q3 2025. Theravance Biopharma is also eligible to receive up to an additional $37.5 million in sales-related milestones and escalating royalties ranging from 14% to 20% on net sales of Yupelri in China. Viatris Inc. (NASDAQ:VTRS) is a healthcare company that operates in 4 segments: Developed Markets, Greater China, JANZ, and Emerging Markets. Theravance Biopharma Inc. (NASDAQ:TBPH) is a biopharmaceutical company that develops and commercializes medicines in the US. While we acknowledge the potential of VTRS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Cision Canada
6 days ago
- Business
- Cision Canada
Viatris Certified as a Great Place to Work® in Canada Français
ETOBICOKE, ON, /CNW/ -- Viatris Inc. (Nasdaq: VTRS) has been certified as a Great Place to Work® in Canada. This recognition highlights Viatris' commitment to fostering a culture where colleagues are enthusiastic about the work they do and feel valued, engaged and motivated. Great Place to Work® is the global authority on workplace culture, employee experience and the leadership behaviors proven to deliver market-leading revenue, employee retention and increased innovation. This recognition is the result of an independent evaluation, which uses a rigorous two-step process that includes an anonymous survey to employees and a specific evaluation of the company's corporate culture, assessing the practices, policies, and HR and leadership culture of the organization. Taking everything into account, 94% of Canadian employees stated they would say this is a great place to work, with 96% stating they are treated fairly regardless of their gender. "Great Place to Work Certification is a highly coveted achievement that requires consistent and intentional dedication to the overall employee experience," says Sarah Lewis-Kulin, the Vice President of Global Recognition at Great Place to Work. She emphasizes that Certification is the sole official recognition earned by the real-time feedback of employees regarding their company culture. "By successfully earning this recognition, it is evident that Viatris stands out as one of the top companies to work for, providing a great workplace environment for its employees." Viatris Canada Country Manager Jeffrey Long states, "We are very proud to receive this certification. It's a reflection of the inclusive, purpose-driven culture we've built together as a team." About Viatris Viatris Inc. (Nasdaq: VTRS) is a global healthcare company uniquely positioned to bridge the traditional divide between generics and brands, combining the best of both to more holistically address healthcare needs globally. With a mission to empower people worldwide to live healthier at every stage of life, we provide access at scale, currently supplying high-quality medicines to approximately 1 billion patients around the world annually and touching all of life's moments, from birth to the end of life, acute conditions to chronic diseases. With our exceptionally extensive and diverse portfolio of medicines, a one-of-a-kind global supply chain designed to reach more people when and where they need them, and the scientific expertise to address some of the world's most enduring health challenges, access takes on deep meaning at Viatris. We are headquartered in the U.S., with global centers in Pittsburgh, Shanghai and Hyderabad, India. Learn more at and and connect with us on LinkedIn, Instagram, YouTube and X. About Great Place to Work Certification™ Great Place to Work® Certification™ is the most definitive "employer-of-choice" recognition that companies aspire to achieve. It is the only recognition based entirely on what employees report about their workplace experience – specifically, how consistently they experience a high-trust workplace. Great Place to Work Certification is recognized worldwide by employees and employers alike and is the global benchmark for identifying and recognizing outstanding employee experience. Every year, more than 10,000 companies across 60 countries apply to get Great Place to Work-Certified. About Great Place To Work ® As the global authority on workplace culture, Great Place to Work® brings 30 years of groundbreaking research and data to help every place become a great place to work for all. Their proprietary platform and For All™ Model helps companies evaluate the experience of every employee, with exemplary workplaces becoming Great Place to Work Certified™ or receiving recognition on a coveted Best Workplaces™ List. Learn more at and follow Great Place To Work on LinkedIn, Twitter, Facebook and Instagram. Forward-Looking Statements This statement includes statements that constitute "forward-looking statements." These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements may include statements regarding new product launches. Because forward-looking statements inherently involve risks and uncertainties, actual future results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to: actions and decisions of healthcare and pharmaceutical regulators; our ability to comply with applicable laws and regulations; changes in healthcare and pharmaceutical laws and regulations in the U.S. and abroad; any regulatory, legal or other impediments to Viatris' ability to bring new products to market; Viatris' or its partners' ability to develop, manufacture, and commercialize products; the scope, timing and outcome of any ongoing legal proceedings, and the impact of any such proceedings; Viatris' failure to achieve expected or targeted future financial and operating performance and results; risks associated with international operations; changes in third-party relationships; the effect of any changes in Viatris' or its partners' customer and supplier relationships and customer purchasing patterns; the impacts of competition; changes in the economic and financial conditions of Viatris or its partners; uncertainties and matters beyond the control of management, including general economic conditions, tariffs and trade restrictions, inflation and exchange rates; and the other risks described in Viatris' filings with the Securities and Exchange Commission (SEC). Viatris routinely uses its website as a means of disclosing material information to the public in a broad, non-exclusionary manner for purposes of the SEC's Regulation Fair Disclosure (Reg FD). Viatris undertakes no obligation to update these statements for revisions or changes after the date of this press release other than as required by law.
Yahoo
11-07-2025
- Business
- Yahoo
Goldman Sachs Reiterates a Hold Rating on Viatris (VTRS) With a $10 PT
Viatris Inc. (NASDAQ:VTRS) is one of the 13 Best Healthcare Stocks to Buy Under $10. In a report released on June 30, Goldman Sachs reiterated a Hold rating on Viatris Inc. (NASDAQ:VTRS) with a price target of $10.00. A healthcare worker in a lab coat, holding a microscope and reflecting on the diagnosis of a patient. The company reported $3.3 billion in total revenues in fiscal Q1 2025, down 11% on a reported basis and down 2% on a divestiture-adjusted operational basis as compared to the same period last year. This drop was primarily attributed to the negative Indore Impact. Management stated that if the Indore Impact is excluded, total revenues would have increased 2% on a divestiture-adjusted operational basis compared to fiscal Q1 2024. Viatris Inc. (NASDAQ:VTRS) also generated around $67 million in new product revenues in fiscal Q1 2025, and expects to deliver new product revenues in 2025 in the $450 million to $550 million range. Viatris Inc. (NASDAQ:VTRS) is a global healthcare company that provides healthcare and pharmaceutical products. The company's medicines and treatments span various therapeutic areas, including oncology, cardiovascular, dermatology, immunology, eye care, gastroenterology, and women's healthcare. Its operations are divided into the following segments: Developed Markets, Greater China, JANZ, and Emerging Markets. While we acknowledge the potential of VTRS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
